Curiox Extends Contract with US NIST... Countdown to Global Standardization of Cell Analysis

Curiox's Laminar Wash™ (hereinafter, LW) has entered the final countdown to establishing a global standard for cell analysis.

Curiox Biosystems (hereinafter, Curiox, CEO Namyong Kim), a global leader in cell analysis process automation, officially announced on the 5th that it has extended its contract with the National Institute of Standards and Technology (NIST) in the United States for participation in the cell analysis standardization consortium and joint research.

Accordingly, Curiox will strengthen its support and cooperation system with NIST for various cell analysis process automation technologies, aiming to publish the "2024 Cell Analysis Standardization White Paper."

A Curiox company representative stated, "Technical collaboration through joint research with NIST has been ongoing since September 2021, and with the full-scale publication of the global cell analysis standard white paper next year, we have signed a two-year extension contract. Once the white paper is published and the standardization recommendations are fully implemented, we expect rapid growth driven by high recognition through global standardization."

NIST is a national research institute under the U.S. Department of Commerce that researches various standards in science and industrial technology fields. It selects, develops, and applies national standards for various technologies and measurement techniques required in industrial sites.

So far, Curiox has supported its cell analysis process automation platform LW technology as a member company of the cell analysis consortium led by NIST. It has also conducted joint research to establish cell analysis standardization. The NIST consortium includes 27 global organizations, such as global pharmaceutical companies leading cell and gene therapy development like AstraZeneca, BMS, KITE (Gilead), and Sanofi; government agencies such as the U.S. FDA and the National Cancer Institute (NCI); and leading medical and bio-device companies like Beckman Coulter, ThermoFisher Scientific, and BD Biosciences.

In fact, the LW technology developed by Curiox implements automation using laminar flow-based microfluidic technology. As a result, it minimizes cell loss and deformation, demonstrates consistent reproducibility of research results without researcher variability, and is being reviewed as a standard operating procedure (SOP) for cell analysis processes in cell and gene therapy.

Regarding this, Curiox CEO Namyong Kim said, "Over the past two years, through technical cooperation in NIST's cell analysis standardization consortium, LW has received encouraging evaluations for improving the standardization of cell analysis processes. We expect that with the publication of the NIST white paper and the NIST standardization recommendations next year, the purchase and adoption of LW products will accelerate, establishing a solid first-mover position in the process automation market, which is estimated to exceed 15 trillion won."

Meanwhile, Curiox submitted a revised securities registration statement to the Financial Services Commission on the 4th, underwritten by Kiwoom Securities, and plans to conduct demand forecasting from July 27 to 28, followed by subscription on August 1 and 2, and to be listed on August 10.